References
- Atsumi R, Suzuki W, Hakusui H. (1991). Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21:1159–69.
- Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5.
- Day AJ, Cañada FJ, Díaz JC, et al. (2000). Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase. FEBS Lett 468:166–70.
- Donaldson GP, Lee SM, Mazmanian SK. (2016). Gut biogeography of the bacterial microbiota. Nat Rev Microbiol 14:20–32.
- Ehrenkranz JR, Lewis NG, Kahn CR, et al. (2005). Phlorizin: a review. Diabetes Metab Res Rev 21:31–8.
- EMA. (2012). EMA Guideline on the investigation of drug interactions. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf [last accessed 12 Mar 2018].
- Fukudo S, Hongo M, Kaneko H, et al. (2011). Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil 23:544–e205.
- Gorboulev V, Schürmann A, Vallon V, et al. (2012). Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187–96.
- Hidalgo M, Oruna-Concha MJ, Kolida S, et al. (2012). Metabolism of anthocyanins by human gut microflora and their influence on gut bacterial growth. J Agric Food Chem 60:3882–90.
- Inoue T, Takemura M, Fushimi N, et al. (2017). Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation. Eur J Pharmacol 806:25–31.
- Isaji M. (2011). SGLT2 inhibitors: molecular design and potential differences in effect. Kidney Int Suppl S14–S19.
- Johanson JF, Kralstein J. (2007). Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 25:599–608.
- Kanai Y, Lee WS, You G, et al. (1994). The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93:397–404.
- Ketudat Cairns JR, Esen A. (2010). β-Glucosidases. Cell Mol Life Sci 67:3389–405.
- Longstreth GF, Thompson WG, Chey WD, et al. (2006). Functional bowel disorders. Gastroenterology 130:1480–91.
- McCallum IJ, Ong S, Mercer-Jones M. (2009). Chronic constipation in adults. BMJ 338:b831.
- MHLW. (2014). Drug interaction guideline for drug development and labeling recommendations. Available from: https://www.pmda.go.jp/files/000206158.pdf [last accessed 12 Mar 2018].
- Németh K, Plumb GW, Berrin JG, et al. (2003). Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans. Eur J Nutr 42:29–42.
- Ozdal T, Sela DA, Xiao J, et al. (2016). The reciprocal interactions between polyphenols and gut microbiota and effects on bioaccessibility. Nutrients 8:78.
- Peris-Ribera JE, Torres-Molina F, Garcia-Carbonell MC, et al. (1991). Pharmacokinetics and bioavailability of diclofenac in the rat. J Pharmacokinet Biopharm 19:647–65.
- Scheen AJ. (2015). Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75:33–59.
- Shi J, Zheng H, Yu J, et al. (2016). SGLT-1 transport and deglycosylation inside intestinal cells are key steps in the absorption and disposition of calycosin-7-O-β-d-glucoside in rats. Drug Metab Dispos 44:283–96.
- Shibazaki T, Tomae M, Ishikawa-Takemura Y, et al. (2012). KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 342:288–96.
- Smith RL. (1966). The biliary excretion and enterohepatic circulation of drugs and other organic compounds. Fortschr Arzneimittelforsch 9:299–360.
- Sun SX, Dibonaventura M, Purayidathil FW, et al. (2011). Impact of chronic constipation on health-related quality of life, work productivity, and healthcare resource use: an analysis of the National Health and Wellness Survey. Dig Dis Sci 56:2688–95.
- Wright EM, Hirayama BA, Loo DF. (2007). Active sugar transport in health and disease. J Intern Med 261:32–43.
- Zhang Y, Liu ZP. (2016). Recent developments of C-aryl glucoside SGLT2 inhibitors. Curr Med Chem 23:832–49.